These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
692 related articles for article (PubMed ID: 10953159)
1. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159 [TBL] [Abstract][Full Text] [Related]
2. Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Harada S; Keller ET; Fujimoto N; Koshida K; Namiki M; Matsumoto T; Mizokami A Prostate; 2001 Mar; 46(4):319-26. PubMed ID: 11241555 [TBL] [Abstract][Full Text] [Related]
3. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686 [TBL] [Abstract][Full Text] [Related]
4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045 [TBL] [Abstract][Full Text] [Related]
5. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. Sato N; Sadar MD; Bruchovsky N; Saatcioglu F; Rennie PS; Sato S; Lange PH; Gleave ME J Biol Chem; 1997 Jul; 272(28):17485-94. PubMed ID: 9211894 [TBL] [Abstract][Full Text] [Related]
6. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY; Ly LH; Peehl DM; Feldman D Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780 [TBL] [Abstract][Full Text] [Related]
7. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Mizokami A; Saiga H; Matsui T; Mita T; Sugita A Endocrinol Jpn; 1992 Jun; 39(3):235-43. PubMed ID: 1425449 [TBL] [Abstract][Full Text] [Related]
8. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616 [TBL] [Abstract][Full Text] [Related]
9. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Ko S; Shi L; Kim S; Song CS; Chatterjee B Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021 [TBL] [Abstract][Full Text] [Related]
10. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991 [TBL] [Abstract][Full Text] [Related]
11. JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-0-tetradecanoylphorbol-13-acetate (TPA). Ikezoe T; Yang Y; Taguchi H; Koeffler HP Br J Cancer; 2004 May; 90(10):2017-24. PubMed ID: 15138488 [TBL] [Abstract][Full Text] [Related]
12. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503 [TBL] [Abstract][Full Text] [Related]
13. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Yeap BB; Krueger RG; Leedman PJ Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1. Diao X; Chen X; Pi Y; Zhang Y; Wang F; Liu P; Gao Y; Wang X; Yang S; Lu S Oncol Rep; 2018 Aug; 40(2):1174-1184. PubMed ID: 29917167 [TBL] [Abstract][Full Text] [Related]
15. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Gong Y; Blok LJ; Perry JE; Lindzey JK; Tindall DJ Endocrinology; 1995 May; 136(5):2172-8. PubMed ID: 7720667 [TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262 [TBL] [Abstract][Full Text] [Related]
17. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Bhattacharyya RS; Krishnan AV; Swami S; Feldman D Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513 [TBL] [Abstract][Full Text] [Related]
18. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Rivest P; Renaud M; Sanderson JT Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724 [TBL] [Abstract][Full Text] [Related]
19. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Warriar N; Pagé N; Koutsilieris M; Govindan MV Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066 [TBL] [Abstract][Full Text] [Related]
20. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts. Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]